<DOC>
	<DOCNO>NCT00263978</DOCNO>
	<brief_summary>Severe veno-occlusive disease ( VOD ) liver life threaten complication blood marrow transplantation . Treatment currently available ( Food Drug Administration [ FDA ] approve ) agent fails case . Recently conduct clinical study indicate patient benefit defibrotide , non-FDA approve agent . This protocol develop research intent , rather ensure defibrotide use blood marrow transplant program Children 's Healthcare Atlanta Emory University safe , effective ethical manner .</brief_summary>
	<brief_title>Defibrotide Compassionate Use Patients With Life Threatening Veno-Occlusive Disease Liver</brief_title>
	<detailed_description>Severe veno-occlusive disease ( VOD ) liver life threaten complication blood marrow transplantation . Treatment currently available ( FDA approve ) agent fails case . Recently conduct clinical study indicate patient benefit defibrotide , non-FDA approve agent . This protocol develop research intent , rather ensure defibrotide use blood marrow transplant program Children 's Healthcare Atlanta Emory University safe , effective ethical manner .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
	<mesh_term>Defibrotide</mesh_term>
	<criteria>Venoocclusive disease liver</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Venous occlusive disease</keyword>
	<keyword>VOD</keyword>
</DOC>